Close this search box.

Eden Wells to lead insights and decision science at Novartis

ARTICLE | Management Tracks

Plus: Nurix appoints Julia Gregory as chair, and updates from Valneva, Alto, Cour and Kronos

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst   

May 22, 2024 12:13 AM UTC

Eden Wells will lead a new division at the U.S. unit of  Novartis AG (SIX:NOVN; NYSE:NVS) as chief insights and decision science officer. Wells, who joined the Swiss pharma in 2019 as VP, head of patient and specialty services, was most recently chief patient experience officer. The new division will use AI and advanced analytics to understand how human behavior impacts care decisions, outcomes and delivery. 

David Lacey stepped down as chair of Nurix Therapeutics Inc. (NASDAQ:NRIX), which is developing targeted protein modulation drugs. Lacey will remain on the board and is succeeded as chair by Julia Gregory, chair and CEO of advisory firm Isometry Advisors Inc…